# Hanover Insurance Group, Inc.: financial statements, quarterly

THG · NYSE · CIK 944695 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/thg.md) · [Financials](/companies/thg/financials.md) · [Filings](/companies/thg/filings.md) · [Insiders](/companies/thg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/thg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,517](/filings/0000950170-24-119438.md) | [1,529 d](/filings/0001193125-26-060983.md) | [1,551](/filings/0000950170-25-061802.md) | [1,537](/filings/0000950170-25-100956.md) | [1,565](/filings/0001193125-25-258501.md) | [1,584 d](/filings/0001193125-26-060983.md) | [1,603](/filings/0001193125-26-197530.md) | [1,654](/filings/0000944695-26-000014.md) | [1,665](/filings/0001193125-25-258501.md) | [1,672 d](/filings/0001193125-26-060983.md) | [1,701](/filings/0001193125-26-197530.md) | [1,726](/filings/0000944695-26-000014.md) |
| Operating income | $m | [13.7](/filings/0000950170-24-119438.md) | [158 d](/filings/0001193125-26-060983.md) | [150](/filings/0000950170-25-061802.md) | [95.4](/filings/0000950170-25-100956.md) | [151](/filings/0001193125-25-258501.md) | [254 d](/filings/0001193125-26-060983.md) | [186](/filings/0001193125-26-197530.md) | [210](/filings/0000944695-26-000014.md) | [248](/filings/0001193125-25-258501.md) | [289 d](/filings/0001193125-26-060983.md) | [250](/filings/0001193125-26-197530.md) | [252](/filings/0000944695-26-000014.md) |
| Income tax | $m | [(9.1)](/filings/0000950170-24-119438.md) | [42.9 d](/filings/0001193125-26-060983.md) | [29.8](/filings/0000950170-25-061802.md) | [10.9](/filings/0000950170-25-100956.md) | [27.6](/filings/0001193125-25-258501.md) | [44.2 d](/filings/0001193125-26-060983.md) | [31.9](/filings/0001193125-26-197530.md) | [41.9](/filings/0000944695-26-000014.md) | [48.5](/filings/0001193125-25-258501.md) | [60.8 d](/filings/0001193125-26-060983.md) | [50.3](/filings/0001193125-26-197530.md) | [53.2](/filings/0000944695-26-000014.md) |
| Net income | $m | [8.6](/filings/0000950170-24-119438.md) | [108 d](/filings/0001193125-26-060983.md) | [116](/filings/0000950170-25-061802.md) | [40.5](/filings/0000950170-25-100956.md) | [102](/filings/0001193125-25-258501.md) | [168 d](/filings/0001193125-26-060983.md) | [128](/filings/0001193125-26-197530.md) | [157](/filings/0000944695-26-000014.md) | [179](/filings/0001193125-25-258501.md) | [199 d](/filings/0001193125-26-060983.md) | [187](/filings/0001193125-26-197530.md) | [192](/filings/0000944695-26-000014.md) |
| Diluted EPS | $ per share | [0.24](/filings/0000950170-24-119438.md) | not reported | [3.18](/filings/0000950170-25-061802.md) | [1.12](/filings/0000950170-25-100956.md) | [2.80](/filings/0001193125-25-258501.md) | not reported | [3.50](/filings/0001193125-26-197530.md) | [4.30](/filings/0000944695-26-000014.md) | [4.90](/filings/0001193125-25-258501.md) | not reported | [5.20](/filings/0001193125-26-197530.md) | [5.38](/filings/0000944695-26-000014.md) |
| Basic EPS | $ per share | [0.24](/filings/0000950170-24-119438.md) | not reported | [3.22](/filings/0000950170-25-061802.md) | [1.13](/filings/0000950170-25-100956.md) | [2.84](/filings/0001193125-25-258501.md) | not reported | [3.56](/filings/0001193125-26-197530.md) | [4.37](/filings/0000944695-26-000014.md) | [4.99](/filings/0001193125-25-258501.md) | not reported | [5.30](/filings/0001193125-26-197530.md) | [5.48](/filings/0000944695-26-000014.md) |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.3](/filings/0000950170-23-058266.md) | [0.3](/filings/0000950170-25-025093.md) | [0.3](/filings/0000950170-24-052129.md) | [0.3](/filings/0000950170-24-089179.md) | [0.4](/filings/0000950170-24-119438.md) | [0.4](/filings/0001193125-26-060983.md) | [0.3](/filings/0000950170-25-061802.md) | [0.2](/filings/0000950170-25-100956.md) | [0.9](/filings/0001193125-25-258501.md) | [1.1](/filings/0000944695-26-000014.md) | [0.2](/filings/0001193125-26-197530.md) | [0.3](/filings/0000944695-26-000014.md) |
| Total assets | $bn | [14.3](/filings/0000950170-23-058266.md) | [14.6](/filings/0000950170-25-025093.md) | [14.6](/filings/0000950170-24-052129.md) | [14.9](/filings/0000950170-24-089179.md) | [15.4](/filings/0000950170-24-119438.md) | [15.3](/filings/0001193125-26-060983.md) | [15.5](/filings/0000950170-25-061802.md) | [15.7](/filings/0000950170-25-100956.md) | [16.8](/filings/0001193125-25-258501.md) | [16.9](/filings/0000944695-26-000014.md) | [16.5](/filings/0001193125-26-197530.md) | [16.9](/filings/0000944695-26-000014.md) |
| Total liabilities | $bn | [12.2](/filings/0000950170-23-058266.md) | [12.1](/filings/0000950170-25-025093.md) | [12.1](/filings/0000950170-24-052129.md) | [12.3](/filings/0000950170-24-089179.md) | [12.5](/filings/0000950170-24-119438.md) | [12.4](/filings/0001193125-26-060983.md) | [12.4](/filings/0000950170-25-061802.md) | [12.5](/filings/0000950170-25-100956.md) | [13.3](/filings/0001193125-25-258501.md) | [13.4](/filings/0000944695-26-000014.md) | [13.0](/filings/0001193125-26-197530.md) | [13.2](/filings/0000944695-26-000014.md) |
| Long-term debt | $bn | not reported | [0.8](/filings/0000950170-25-025093.md) | not reported | not reported | not reported | [0.7](/filings/0001193125-26-060983.md) | [0.7](/filings/0000950170-25-061802.md) | [0.3](/filings/0000950170-25-100956.md) | [0.8](/filings/0001193125-25-258501.md) | [0.8](/filings/0000944695-26-000014.md) | [0.8](/filings/0001193125-26-197530.md) | [0.8](/filings/0000944695-26-000014.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001193125-26-060983.md) | [0.1](/filings/0000950170-25-061802.md) | [0.4](/filings/0000950170-25-100956.md) | [0.4](/filings/0001193125-25-258501.md) | [0.4](/filings/0000944695-26-000014.md) | [0.1](/filings/0001193125-26-197530.md) | [0.1](/filings/0000944695-26-000014.md) |
| Shareholders' equity | $bn | [2.1](/filings/0000950170-24-119438.md) | [2.5](/filings/0001193125-26-060983.md) | [2.5](/filings/0000950170-25-061802.md) | [2.6](/filings/0000950170-25-100956.md) | [2.9](/filings/0001193125-25-258501.md) | [2.8](/filings/0001193125-26-060983.md) | [3.0](/filings/0001193125-26-197530.md) | [3.2](/filings/0000944695-26-000014.md) | [3.4](/filings/0001193125-25-258501.md) | [3.6](/filings/0000944695-26-000014.md) | [3.6](/filings/0001193125-26-197530.md) | [3.7](/filings/0000944695-26-000014.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [225 d](/filings/0000950170-24-119438.md) | [92.7 d](/filings/0001193125-26-060983.md) | [58.7](/filings/0000950170-25-061802.md) | [140 d](/filings/0000950170-25-100956.md) | [395 d](/filings/0001193125-25-258501.md) | [214 d](/filings/0001193125-26-060983.md) | [38.9](/filings/0001193125-26-197530.md) | [207 d](/filings/0000944695-26-000014.md) | [554 d](/filings/0001193125-25-258501.md) | [378 d](/filings/0001193125-26-060983.md) | [119](/filings/0001193125-26-197530.md) | [212 d](/filings/0000944695-26-000014.md) |
| Capital expenditure | $m | [2.9 d](/filings/0000950170-24-119438.md) | [2.2 d](/filings/0001193125-26-060983.md) | [2.6](/filings/0000950170-25-061802.md) | [2.2 d](/filings/0000950170-25-100956.md) | [2.4 d](/filings/0001193125-25-258501.md) | [3.0 d](/filings/0001193125-26-060983.md) | [1.8](/filings/0001193125-26-197530.md) | [1.7 d](/filings/0000944695-26-000014.md) | [3.0 d](/filings/0001193125-25-258501.md) | [1.2 d](/filings/0001193125-26-060983.md) | [3.5](/filings/0001193125-26-197530.md) | [2.9 d](/filings/0000944695-26-000014.md) |
| Dividends paid | $m | [29.0 d](/filings/0000950170-24-119438.md) | [30.3 d](/filings/0001193125-26-060983.md) | [30.5](/filings/0000950170-25-061802.md) | [30.6 d](/filings/0000950170-25-100956.md) | [30.6 d](/filings/0001193125-25-258501.md) | [32.4 d](/filings/0001193125-26-060983.md) | [32.4](/filings/0001193125-26-197530.md) | [32.3 d](/filings/0000944695-26-000014.md) | [32.2 d](/filings/0001193125-25-258501.md) | [33.7 d](/filings/0001193125-26-060983.md) | [33.5](/filings/0001193125-26-197530.md) | [33.1 d](/filings/0000944695-26-000014.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-23-058266.md) | [0.0 d](/filings/0001193125-26-060983.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-258501.md) | [26.7 d](/filings/0001193125-26-060983.md) | [11.0](/filings/0001193125-26-197530.md) | [27.6 d](/filings/0000944695-26-000014.md) | [36.0 d](/filings/0001193125-25-258501.md) | [54.6 d](/filings/0001193125-26-060983.md) | [86.9](/filings/0001193125-26-197530.md) | [55.0 d](/filings/0000944695-26-000014.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [36.1](/filings/0000950170-23-058266.md) | [35.6](/filings/0000950170-24-052129.md) | [35.7](/filings/0000950170-24-089179.md) | [36.1](/filings/0000950170-24-119438.md) | [36.3](/filings/0000950170-25-061802.md) | [36.3](/filings/0000950170-25-100956.md) | [36.5](/filings/0001193125-25-258501.md) | [36.6](/filings/0001193125-26-197530.md) | [36.5](/filings/0000944695-26-000014.md) | [36.4](/filings/0001193125-25-258501.md) | [35.9](/filings/0001193125-26-197530.md) | [35.6](/filings/0000944695-26-000014.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 34,820,221 at 2026-07-27, from the cover of the [10-Q filed 2026-07-29](/filings/0000944695-26-000014.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.